Peroxisome proliferator-activated receptor-γ ligands regulate endothelial membrane superoxide production

被引:222
作者
Hwang, JN
Kleinhenz, DJ
Lassègue, B
Griendling, KK
Dikalov, S
Hart, CM
机构
[1] Atlanta Vet Affairs Med Ctr, Pulm Sect, Div Pulm & Crit Care Med, Decatur, GA 30033 USA
[2] Emory Univ, Med Ctr, Div Pulm & Crit Care Med, Decatur, GA 30033 USA
[3] Emory Univ, Div Cardiol, Atlanta, GA 30322 USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY | 2005年 / 288卷 / 04期
关键词
reduced nicotinamide adenine dinucleotide phosphate oxidase; copper/zinc superoxide dismutase; nitric oxide; endothelial cells;
D O I
10.1152/ajpcell.00474.2004
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Recently, we demonstrated that the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands, either 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)) or ciglitazone, increased endothelial nitric oxide (center dot NO) release without altering endothelial nitric oxide synthase ( eNOS) expression ( 4). However, the precise molecular mechanisms of PPAR-gamma-stimulated endothelial center dot NO release remain to be defined. Superoxide anion radical (O(2)(-)center dot) combines with center dot NO to decrease center dot NO bioavailability. NADPH oxidase, which produces O(2)(-)center dot, and Cu/Zn-superoxide dismutase ( Cu/Zn-SOD), which degrades O(2)(-)center dot, thereby contribute to regulation of endothelial cell center dot NO metabolism. Therefore, we examined the ability of PPAR-gamma ligands to modulate endothelial O(2)(-)center dot metabolism through alterations in the expression and activity of NADPH oxidase or Cu/Zn-SOD. Treatment with 10 mu M 15d-PGJ(2) or ciglitazone for 24 h decreased human umbilical vein endothelial cell ( HUVEC) membrane NADPH-dependent O(2)(-)center dot production detected with electron spin resonance spectroscopy. Treatment with 15d-PGJ(2) or ciglitazone also reduced relative mRNA levels of the NADPH oxidase subunits, nox-1, gp91(phox) (nox-2), and nox-4, as measured using real-time PCR analysis. Concordantly, Western blot analysis demonstrated that 15d-PGJ(2) or ciglitazone decreased nox-2 and nox-4 protein expression. PPAR-gamma ligands also stimulated both activity and expression of Cu/Zn-SOD in HUVEC. These data suggest that in addition to any direct effects on endothelial center dot NO production, PPAR-gamma ligands enhance endothelial center dot NO bioavailability, in part by altering endothelial O(2)(-)center dot metabolism through suppression of NADPH oxidase and induction of Cu/Zn-SOD. These findings further elucidate the molecular mechanisms by which PPAR-gamma ligands directly alter vascular endothelial function.
引用
收藏
页码:C899 / C905
页数:7
相关论文
共 37 条
[1]   Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase [J].
Ago, T ;
Kitazono, T ;
Ooboshi, H ;
Iyama, T ;
Han, YH ;
Takada, J ;
Wakisaka, M ;
Ibayashi, S ;
Utsumi, H ;
Iida, M .
CIRCULATION, 2004, 109 (02) :227-233
[2]   PPARγ activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes [J].
Bagi, Z ;
Koller, A ;
Kaley, G .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2004, 286 (02) :H742-H748
[3]   Peroxisome proliferator-activated receptor gamma (PPARγ) activation and its consequences in humans [J].
Bar-Tana, J .
TOXICOLOGY LETTERS, 2001, 120 (1-3) :9-19
[4]   Peroxisome proliferator-activated receptor γ ligands increase release of nitric oxide from endothelial cells [J].
Calnek, DS ;
Mazzella, L ;
Roser, S ;
Roman, J ;
Hart, CM .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (01) :52-57
[5]  
Calnek DS, 2003, FASEB J, V17, pA120
[6]   Differential activation of peroxisome proliferator-activated receptor-γ by troglitazone and rosiglitazone [J].
Camp, HS ;
Li, O ;
Wise, SC ;
Hong, YH ;
Frankowski, CL ;
Shen, XQ ;
Vanbogelen, R ;
Leff, T .
DIABETES, 2000, 49 (04) :539-547
[7]  
Chen CC, 2001, J FORMOS MED ASSOC, V100, P176
[8]   Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone -: Evidence for involvement of peroxisome proliferator-activated receptor (PPAR)γ-dependent and PPARγ-independent signaling pathways [J].
Cho, DH ;
Choi, YJ ;
Jo, SA ;
Jo, I .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (04) :2499-2506
[9]   Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice [J].
Collins, AR ;
Meehan, WP ;
Kintscher, U ;
Jackson, S ;
Wakino, S ;
Noh, G ;
Palinski, W ;
Hsueh, WA ;
Law, RE .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (03) :365-371
[10]   Troglitazone, an insulin sensitizer, increases forearm blood flow in humans [J].
Fujishima, S ;
Ohya, Y ;
Nakamura, Y ;
Onaka, U ;
Abe, I ;
Fujishima, M .
AMERICAN JOURNAL OF HYPERTENSION, 1998, 11 (09) :1134-1137